Improved Postoperative Speech Recognition and Processor Use With Early Cochlear Implant Activation.

Autor:	Patro A; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee., Lindquist NR; Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas., Holder JT; Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Freeman MH; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee., Gifford RH; Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Tawfik KO; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee., O'Malley MR; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee., Bennett ML; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee., Haynes DS; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee., Perkins EL; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Jazyk:	angličtina
Zdroj:	Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology [Otol Neurotol] 2024 Apr 01; Vol. 45 (4), pp. 386-391. Date of Electronic Publication: 2024 Feb 28.
DOI:	10.1097/MAO.0000000000004150
Abstrakt:	Objective: To report speech recognition outcomes and processor use based on timing of cochlear implant (CI) activation. Study Design: Retrospective cohort. Setting: Tertiary referral center. Patients: A total of 604 adult CI recipients from October 2011 to March 2022, stratified by timing of CI activation (group 1: ≤10 d, n = 47; group 2: >10 d, n = 557). Main Outcome Measures: Average daily processor use; Consonant-Nucleus-Consonant (CNC) and Arizona Biomedical (AzBio) in quiet at 1-, 3-, 6-, and 12-month visits; time to peak performance. Results: The groups did not differ in sex ( p = 0.887), age at CI ( p = 0.109), preoperative CNC ( p = 0.070), or preoperative AzBio in quiet ( p = 0.113). Group 1 had higher median daily processor use than group 2 at the 1-month visit (12.3 versus 10.7 h/d, p = 0.017), with no significant differences at 3, 6, and 12 months. The early activation group had superior median CNC performance at 3 months (56% versus 46%, p = 0.007) and 12 months (60% versus 52%, p = 0.044). Similarly, the early activation group had superior median AzBio in quiet performance at 3 months (72% versus 59%, p = 0.008) and 12 months (75% versus 68%, p = 0.049). Both groups were equivalent in time to peak performance for CNC and AzBio. Earlier CI activation was significantly correlated with higher average daily processor use at all follow-up intervals. Conclusion: CI activation within 10 days of surgery is associated with increased early device usage and superior speech recognition at both early and late follow-up visits. Timing of activation and device usage are modifiable factors that can help optimize postoperative outcomes in the CI population. Competing Interests: Conflict of interest: J.T.H. is a consultant for Cochlear and serves on the advisory board for Advanced Bionics and MED-EL. M.H.F. is an advisor for Endotheia, Inc. K.O.T. has served as an advisory board member for GlaxoSmithKline. D.S.H. is a consultant for Advanced Bionics, Cochlear Americas, MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. R.H.G. is a consultant for Advanced Bionics, Akouos, and Cochlear Americas; is on the clinical advisory board for Frequency Therapeutics; and is on the Board of Directors for the American Auditory Society. (Copyright © 2024, Otology & Neurotology, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu